Trials / Completed
CompletedNCT02182206
An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours
A Phase I Open Label Dose Escalation Study of Continuous Once-daily or Twice Daily Oral Treatment With BIBF 1120 in Patients With Advanced Solid Tumours
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Maximum Tolerated Dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120, pharmacodynamic parameters (Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI))
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIBF 1120 |
Timeline
- Start date
- 2003-06-01
- Primary completion
- 2005-06-01
- First posted
- 2014-07-08
- Last updated
- 2014-07-18
Source: ClinicalTrials.gov record NCT02182206. Inclusion in this directory is not an endorsement.